Mehran Karimi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1703420/publications.pdf

Version: 2024-02-01

369 papers	6,677 citations	94269 37 h-index	114278 63 g-index
377 all docs	377 docs citations	377 times ranked	6168 citing authors

#	Article	IF	Citations
1	Primary HBB gene mutation severity and longâ€term outcomes in a global cohort of Î²â€thalassaemia. British Journal of Haematology, 2022, 196, 414-423.	1.2	8
2	Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERSâ€IPS study. Journal of Thrombosis and Haemostasis, 2022, 20, 1106-1114.	1.9	5
3	EFFICACY AND SAFETY OF SINOPHARM VACCINE FOR SARS-COV-2 AND BREAKTHROUGH INFECTIONS IN IRANIAN PATIENTS WITH HEMOGLOBINOPATHIES: A PRELIMINARY REPORT. Mediterranean Journal of Hematology and Infectious Diseases, 2022, 14, e2022026.	0.5	8
4	Oncogenic and tumor suppressor genes expression in myeloproliferative neoplasms: The hidden side of a complex pathology. Journal of Clinical Laboratory Analysis, 2022, 36, e24289.	0.9	1
5	Random Forest Clustering Identifies Three Subgroups of Î²-Thalassemia with Distinct Clinical Severity. Thalassemia Reports, 2022, 12, 14-23.	0.1	3
6	Risk of mortality from anemia and iron overload in nontransfusionâ€dependent Î²â€thalassemia. American Journal of Hematology, 2022, 97, .	2.0	19
7	The clinical characteristics, biochemical parameters and insulin response to oral glucose tolerance test (OGTT) in 25 transfusion dependent Î²-thalassemia (TDT) patients recently diagnosed with diabetes mellitus (DM).. Acta Biomedica, 2022, 92, e2021488.	0.2	4
8	Screening for glucose dysregulation in Î²-thalassemia major (Î²-TM): An update of current evidences and personal experience.. Acta Biomedica, 2022, 93, e2022158.	0.2	2
9	The The use of oral glucose-lowering agents (GLAs) in Î²-thalassemia patients with diabetes: Preliminary data from a retrospective study of ICET-A Network.. Acta Biomedica, 2022, 93, e2022162.	0.2	1
10	A complication risk score to evaluate clinical severity of thalassaemia syndromes. British Journal of Haematology, 2021, 192, 626-633.	1.2	7
11	Effects of three months of treatment with vitamin E and N-acetyl cysteine on the oxidative balance in patients with transfusion-dependent Î²-thalassemia. Annals of Hematology, 2021, 100, 635-644.	0.8	4
12	Bayesian spatial modeling of transfusion-dependent Î²-thalassemia incidence rate in Fars Province, Southern Iran. Spatial and Spatio-temporal Epidemiology, 2021, 36, 100389.	0.9	2
13	The effect of curcumin on serum copper, zinc, and zinc/copper ratio in patients with Î²-thalassemia intermedia: a randomized double-blind clinical trial. Annals of Hematology, 2021, 100, 627-633.	0.8	3
14	A cost-effectiveness analysis of the prophylaxis versus on-demand regimens in severe hemophilia A patients under 12 years old in southern Iran. Hematology, 2021, 26, 240-248.	0.7	1
15	Trace Elements in Children with Acute Lymphoblastic Leukemia. Asian Pacific Journal of Cancer Prevention, 2021, 22, 43-47.	0.5	9
16	Survival and causes of death in 2,033 patients with non-transfusion-dependent Î²-thalassemia. Haematologica, 2021, 106, 2489-2492.	1.7	25
17	Incidence Rate of COVID-19 Infection in Hemoglobinopathies: A Systematic Review and Meta-analysis. Hemoglobin, 2021, 45, 371-379.	0.4	12
18	Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A. Haemophilia, 2021, 27, e441-e449.	1.0	1

#	Article	IF	Citations
19	Sickle cell disease and COVIDâ€19: Susceptibility and severity. Pediatric Blood and Cancer, 2021, 68, e29075.	0.8	25
20	Vitamin D level, lipid profile, and vitamin D receptor and transporter gene variants in sickle cell disease patients from Kurdistan of Iraq. Journal of Clinical Laboratory Analysis, 2021, 35, e23908.	0.9	4
21	Expression of the immune checkpoint receptors CTLA-4, LAG-3, and TIM-3 in Î²-thalassemia major patients: correlation with alloantibody production and regulatory T cells (Tregs) phenotype. Annals of Hematology, 2021, 100, 2463-2469.	0.8	0
22	Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. Blood Advances, 2021, 5, 2987-3001.	2.5	11
23	Comparison of the clinical features and outcome of children with hemophagocytic lymphohistiocytosis (HLH) secondary to visceral leishmaniasis and primary HLH: a single-center study. BMC Infectious Diseases, 2021, 21, 732.	1.3	9
24	Epidemiologic study of patients with thrombotic events referred to a tertiary hospital in Southern Iran. Heliyon, 2021, 7, e07734.	1.4	0
25	Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent Î²-thalassemia: a comprehensive single-center experience. Annals of Hematology, 2021, 100, 2901-2907.	0.8	5
26	Coronavirus disease 2019 (COVID-19) severity in patients with thalassemias: A Nationwide Iranian Experience. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021008.	0.5	12
27	The Prevalence of glucose dysregulations (GDs) in patients with Î²-thalassemias in different countries: A preliminary ICET-A survey. Acta Biomedica, 2021, 92, e2021240.	0.2	2
28	The Prevalence of Hypothyroidism among Patients With Î²-Thalassemia: A Systematic Review and Meta-Analysis of Cross-Sectional Studies. Hemoglobin, 2021, 45, 275-286.	0.4	4
29	Clinical and genetic characteristics of hemoglobin H disease in Iran. Pediatric Hematology and Oncology, 2021, , 1-11.	0.3	0
30	TET2, DNMT3A, IDH1, and JAK2 Mutation in Myeloproliferative Neoplasms in southern Iran.. International Journal of Organ Transplantation Medicine, 2021, 12, 12-20.	0.5	0
31	An electrochemical signal-on apta-cyto-sensor for quantitation of circulating human MDA-MB-231 breast cancer cells by transduction of electro-deposited non-spherical nanoparticles of gold. Journal of Pharmaceutical and Biomedical Analysis, 2020, 178, 112948.	1.4	29
32	Evaluation of endocrine complications in beta-thalassemia intermedia (Î²-TI): a cross-sectional multicenter study. Endocrine, 2020, 69, 220-227.	1.1	8
33	Evaluation of Efficacy, Safety, and Satisfaction Taking Deferasirox Twice Daily Versus Once Daily in Patients With Transfusion-Dependent Thalassemia. Journal of Pediatric Hematology/Oncology, 2020, 42, 23-26.	0.3	7
34	Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients. Journal of Thrombosis and Haemostasis, 2020, 18, 815-824.	1.9	24
35	Combined X-ray radiotherapy and laser photothermal therapy of melanoma cancer cells using dual-sensitization of platinum nanoparticles. Journal of Photochemistry and Photobiology B: Biology, 2020, 203, 111737.	1.7	48
36	Ocular findings in patients with transfusion-dependent Î²-thalassemia in southern Iran. BMC Ophthalmology, 2020, 20, 376.	0.6	4

#	Article	IF	Citations
37	Association of Exon 14 of the SOX6 Gene Sequence Variations with Response to Hydroxyurea Therapy in Patients Carrying Non Transfusion-Dependent Thalassemia. Hemoglobin, 2020, 44, 406-410.	0.4	1
38	A A Multicentre ICET-A Study of Confirmed SARS-CoV-2 Infection in Patients with Hemoglobinopathies: Preliminary Data from 10 Countries. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020046.	0.5	47
39	Bone mineral density in transfusion-dependent thalassemia patients and its associated factors in Southern Iran. Archives of Osteoporosis, 2020, 15, 148.	1.0	2
40	Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERSâ€IPS, an international and collaborative crossâ€sectional study. Journal of Thrombosis and Haemostasis, 2020, 18, 2145-2154.	1.9	20
41	Prevalence and mortality in Î²â€thalassaemias due to outbreak of novel coronavirus disease (COVIDâ€19): the nationwide Iranian experience. British Journal of Haematology, 2020, 190, e137-e140.	1.2	35
42	CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN Î²-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020006.	0.5	18
43	Antithrombotic prophylaxis in children and adolescents' patients with SARS-CoV-2 (COVID-19) infection: A practical guidance for clinicians. Acta Biomedica, 2020, 91, e2020170.	0.2	6
44	Parameters of tissue iron overload and cardiac function in patients with thalassemia major and intermedia. Acta Haematologica Polonica, 2020, 51, 95-101.	0.1	2
45	Frequency of Thyroid Nodules in Patients with ?-Thalassemias in Southern Iran. Acta Endocrinologica, 2020, 16, 68-73.	0.1	2
46	Case series of bloody sweating; a scary event for families. Acta Haematologica Polonica, 2020, 51, 258-260.	0.1	2
47	Water Only Sequence: An Accurate Method to Estimate Hepatic Siderosis in Patients with Thalassemia Major and Intermedia. Iranian Journal of Radiology, 2020, 17, .	0.1	0
48	Implications of SARSr-CoV 2 infection in thalassemias: Do patients fall into the "high clinical risk" category?. Acta Biomedica, 2020, 91, 50-56.	0.2	13
49	Prevalence and clinical features of COVID-19 in Iranian patients with congenital coagulation disorders. Blood Transfusion, 2020, 18, 413-414.	0.3	2
50	A comprehensive update of ICET-A Network on COVID-19 in thalassemias: what we know and where we stand. Acta Biomedica, 2020, 91, e2020026.	0.2	5
51	Congenital Bleeding Disorders amid the COVID-19 pandemic: Open questions and recommendations. Acta Biomedica, 2020, 91, e2020028.	0.2	2
52	Prevalence and severity of Coronavirus disease 2019 (COVID-19) in Transfusion Dependent and Non-Transfusion Dependent Î²-thalassemia patients and effects of associated comorbidities: an Iranian nationwide study. Acta Biomedica, 2020, 91, e2020007.	0.2	5
53	Frequency of silent brain lesions and aspirin protection evaluation over 3Âyears follow-up in beta thalassemia patients. Annals of Hematology, 2019, 98, 2267-2271.	0.8	7
54	Inhibitors against rFVIIa in patients with severe congenital FVII deficiency: A case series. Haemophilia, 2019, 25, e345-e349.	1.0	6

#	Article	IF	Citations
55	Correlation of bleeding score with frequency and severity of bleeding symptoms in FXIII deficiency assessing by the ISTH Bleeding Assessment Tool. Transfusion and Apheresis Science, 2019, 58, 495-497.	0.5	4
56	A Homozygous Mutation on the HBA1 Gene Coding for Hb Charlieu (HBA1: c.320T>C) Together with Î²-Thalassemia Trait Results in Severe Hemolytic Anemia. Hemoglobin, 2019, 43, 77-82.	0.4	0
57	Enhanced melanoma cell-killing by combined phototherapy/radiotherapy using a mesoporous platinum nanostructure. Photodiagnosis and Photodynamic Therapy, 2019, 28, 300-307.	1.3	11
58	Evaluation of the Effect of Support-Training System of Peer Group on Promotion of Self-Care in Î²-Thalassemia Major Patients in Southern Iran. Hemoglobin, 2019, 43, 198-203.	0.4	3
59	Prevalence of endocrine disorders and their associated factors in transfusion-dependent thalassemia patients: a historical cohort study in Southern Iran. Journal of Endocrinological Investigation, 2019, 42, 1467-1476.	1.8	20
60	Association between Helicobacter pylori Infection and Iron Deficiency Anemia in School-aged Iranian Children. Indian Pediatrics, 2019, 56, 387-389.	0.2	10
61	A retrospective study on clinical manifestations of neonates with FXIII-A deficiency. Blood Cells, Molecules, and Diseases, 2019, 77, 78-81.	0.6	4
62	Global longitudinal strain as an Indicator of cardiac Iron overload in thalassemia patients. Cardiovascular Ultrasound, 2019, 17, 24.	0.5	22
63	Evaluation of a self-nanoemulsifying docetaxel delivery system. Biomedicine and Pharmacotherapy, 2019, 109, 2427-2433.	2.5	47
64	FoxO3a gene down-regulation in pathogenesis of pediatric acute lymphoblastic leukemia. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 381.	0.1	0
65	The efficacy of knee orthoses following anterior cruciate ligament injury: a review of literature. Muscles, Ligaments and Tendons Journal, 2019, 09, 282.	0.1	0
66	Down-Regulation of Gene in Pediatric Acute Lymphoblastic Leukemia Patients from South of Iran. International Journal of Hematology-Oncology and Stem Cell Research, 2019, 13, 20-24.	0.3	0
67	Marital status and paternity in patients with Transfusion- Dependent Thalassemia (TDT) and Non Transfusion-Dependent Thalassemia (NTDT): an ICET - A survey in different countries. Acta Biomedica, 2019, 90, 225-237.	0.2	3
68	Modified Primary Prophylaxis in Previously Untreated Patients With Severe Hemophilia A in Iran. Journal of Pediatric Hematology/Oncology, 2018, 40, 188-191.	0.3	5
69	Successful delivery in an patient with afibrinogenemia after three abortions: A case report and review of the literature. Haemophilia, 2018, 24, e63-e66.	1.0	8
70	Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. Journal of Thrombosis and Haemostasis, 2018, 16, 778-790.	1.9	23
71	On the use of substandard medicines in hematology: An emerging concern in the Middle East and North Africa region. European Journal of Internal Medicine, 2018, 48, e40-e41.	1.0	2
72	Factor <scp>XIII</scp> deficiency diagnosis: Challenges and tools. International Journal of Laboratory Hematology, 2018, 40, 3-11.	0.7	47

#	Article	IF	Citations
73	Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency. Journal of Thrombosis and Haemostasis, 2018, 16, 253-261.	1.9	33
74	Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial. Transfusion, 2018, 58, 413-422.	0.8	19
75	Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. Hematology, 2018, 23, 417-422.	0.7	3
76	Thrombosis in pediatric malignancy. Blood Coagulation and Fibrinolysis, 2018, 29, 596-601.	0.5	7
77	Relationship of the Interaction Between Two Quantitative Trait Loci with Î³-Globin Expression in Î²-Thalassemia Intermedia Patients. Hemoglobin, 2018, 42, 108-112.	0.4	1
78	Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology, 2018, 97, 1919-1924.	0.8	8
79	An investigation on acoustic noise emitted by induction motors due to magnetic sources. , 2018, , .		3
80	Epidemiologic study of patients with thrombotic events referred to Dastgheib Thrombosis and Hemostasis Research Center in south of Iran (2015-2017). Thrombosis Research, 2018, 164, S218.	0.8	0
81	An ICET- A survey on Hypoparathyroidism in Patients with Thalassaemia Major and Intermedia: A preliminary report. Acta Biomedica, 2018, 88, 435-444.	0.2	12
82	Prediction of Anti-FVIII Inhibitor Persistence By Anti-FVIII IgG Subclasses in Patients with Severe Hemophilia â€" A in the Sippet Cohort Study. Blood, 2018, 132, 384-384.	0.6	0
83	Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease.. Blood, 2018, 132, 1184-1184.	0.6	0
84	Evaluation of Endocrine Complications in Beta-Thalassemia Intermedia Patients: A Cross Sectional Multi-Center Study. Blood, 2018, 132, 2343-2343.	0.6	1
85	Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project. Blood, 2018, 132, 2464-2464.	0.6	0
86	Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project). Blood, 2018, 132, 2465-2465.	0.6	2
87	Survival Rate in Thalassemia Major Patients: Difference between Date of Diagnosis and Date of Birth as an Index Date for Calculating Follow Up. Iranian Journal of Public Health, 2018, 47, 768-769.	0.3	0
88	Design and Production of Two-piece Thyroid-neck Phantom by the Concurrent Use of Epoxy Resin and Poly(methyl methacrylate) Soft Tissue Equivalent Materials. Journal of Biomedical Physics and Engineering, 2018, 8, 217-222.	0.5	0
89	Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients. Journal of Pharmacopuncture, 2018, 21, 76-81.	0.4	0
90	The frequency of hypothyroidism and its relationship with HCV positivity in patients with thalassemia major in southern Iran. Acta Biomedica, 2018, 89, 55-60.	0.2	2

#	Article	IF	Citations
91	Intrathecal Autologous Bone Marrow-Derived Hematopoietic Stem Cell Therapy in Neurological Diseases. International Journal of Organ Transplantation Medicine, 2018, 9, 157-167.	0.5	4
92	Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients. Journal of Pharmacopuncture, 2018, 21, 76-81.	0.4	1
93	Hypo-pigmented mycosis fungoides is a rare malignancy in pediatrics. Dermatology Online Journal, 2018, 24, .	0.2	2
94	Evaluation of Heart Function in Patients With Hemophilia. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 374-378.	0.7	5
95	Quality of Life in Children and Adolescents With Rare Bleeding Disorders in Southern Iran. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 652-656.	0.7	7
96	Relationship Between Some Single-nucleotide Polymorphism and Response to Hydroxyurea Therapy in Iranian Patients With Î²-Thalassemia Intermedia. Journal of Pediatric Hematology/Oncology, 2017, 39, e171-e176.	0.3	9
97	Safety and effectiveness of room temperature stable recombinant factor <scp>VII</scp>a in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study. Haemophilia, 2017, 23, 575-582.	1.0	2
98	Optimal design of a Hybrid Excited Doubly Salient Permanent Magnet generator for wind turbine application. , 2017, , .		4
99	Residual pyruvate kinase activity in PKLRâ€«deficient erythroid precursors of a patient suffering from severe haemolytic anaemia. European Journal of Haematology, 2017, 98, 584-589.	1.1	5
100	Gonadal dysfunction in adult male patients with thalassemia major: an update for clinicians caring for thalassemia. Expert Review of Hematology, 2017, 10, 1095-1106.	1.0	24
101	A large case series on surgical outcomes in congenital factor XIII deficiency patients in Iran. Journal of Thrombosis and Haemostasis, 2017, 15, 2300-2305.	1.9	4
102	Evaluation of Proteinuria in Î²-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox. Journal of Pediatric Hematology/Oncology, 2017, 39, e11-e14.	0.3	3
103	Real-World Early Treatment with Room Temperatureâ€“Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7â„¢ Post Hoc Analyses. TH Open, 2017, 01, e130-e138.	0.7	1
104	Correlation of serum ferritin levels with hepatic MRI T2 and liver iron concentration in nontransfusion beta-thalassemia intermediate patients: A contemporary issue. Pediatric Hematology and Oncology, 2017, 34, 292-297.	0.3	13
105	A comparison of heart function and arrhythmia in clinically asymptomatic patients with beta thalassemia intermedia and beta thalassemia major. Hematology, 2017, 22, 25-29.	0.7	10
106	Transcranial Doppler Screening in 50 Patients With Sickle Cell Hemoglobinopathies in Iran. Journal of Pediatric Hematology/Oncology, 2017, 39, 506-512.	0.3	4
107	Adverse Effects of Prolonged Sitting Behavior on the General Health of Office Workers. Journal of Lifestyle Medicine, 2017, 7, 69-75.	0.3	74
108	Trends in 5-, 10-, 20-, and 30-Year Survival Rates of Beta-Thalassemia Patients in Southern Iran, 1995-2016: A Retrospective Cohort Study. Journal of Public Health Research, 2017, 6, jphr.2017.1001.	0.5	3

#	Article	IF	Citations
109	Comparison of Quality of Life in Patients with Î²-Thalassemia Intermedia and Î²-Thalassemia Major in Southern Iran. Hemoglobin, 2017, 41, 169-174.	0.4	12
110	Phenotype Report on Patients with Congenital Factor V Deficiency in Southern Iran in the recent ten years experience. Turkish Journal of Haematology, 2017, 34, 250-253.	0.2	1
111	A Significant Breakthrough in the Incidence of Childhood Cancers and Evaluation of its Risk Factors in Southern Iran. Indian Journal of Medical and Paediatric Oncology, 2017, 38, 158-164.	0.1	1
112	Evaluation of Plasma Platelet Microparticles in Thrombotic Thrombocytopenic Purpura. Annals of Clinical and Laboratory Science, 2017, 47, 62-67.	0.2	4
113	A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 184-190.	0.7	18
114	Evaluation of Thrombin Generation Assay in Patients With Hemophilia. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 322-326.	0.7	11
115	The diagnostic approach to central adrenocortical insufficiency (CAI) in thalassemia. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016026.	0.5	3
116	Evaluation of Knowledge of Patients with Hemophilia Regarding Their Diseases and Treatment in Iran. Turkish Journal of Haematology, 2016, 33, 355-356.	0.2	2
117	Î²-thalassemia distribution in the old world: a historical standpoint of an ancient disease. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017018.	0.5	193
118	A comparison between MRI, sonography and Functional Independence Score in Haemophilia methods in diagnosis, evaluation and classification of arthropathy in severe haemophilia A and B. Blood Coagulation and Fibrinolysis, 2016, 27, 131-135.	0.5	5
119	Severe hemophilia in a girl infant with mosaic Turner syndrome and persistent hyperplastic primary vitreous. Blood Coagulation and Fibrinolysis, 2016, 27, 352-353.	0.5	8
120	Efficacy and safety of factor eight inhibitor bypassing activity prophylaxis evaluation in young patients with hemophilia and high titer inhibitor. Blood Coagulation and Fibrinolysis, 2016, 27, 232-233.	0.5	0
121	A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. New England Journal of Medicine, 2016, 374, 2054-2064.	13.9	414
122	Relationship between the results of laser-induced breakdown spectroscopy and dynamical mechanical analysis in composite solid propellants during their aging. Applied Optics, 2016, 55, 4362.	2.1	23
123	Evaluation of the Relationship Between Hb F Levels and Nucleated Red Blood Cells with Morbidity in Non Transfusion-Dependent Thalassemia Patients. Hemoglobin, 2016, 40, 250-256.	0.4	3
124	Frequency of silent cerebral ischemia in patients with transfusion-dependent Î²-thalassemia major compared to healthy individuals. Annals of Hematology, 2016, 95, 1387-1387.	0.8	6
125	A Number of Cases in Iran Presenting with Coinheritance of Hemoglobin-H Disease and Beta-Thalassemia Minor. Hemoglobin, 2016, 40, 316-318.	0.4	5
126	Women with congenital factor <scp>VII</scp> deficiency: clinical phenotype and treatment options from two international studies. Haemophilia, 2016, 22, 752-759.	1.0	36

#	Article	IF	Citations
127	Evaluation of bone mineral density in patients with hemoglobin H disease. Annals of Hematology, 2016, 95, 1329-1332.	0.8	2
128	The frequency of silent cerebral ischemia in patients with transfusion-dependent Î²-thalassemia major. Annals of Hematology, 2016, 95, 135-139.	0.8	18
129	A novel approach for investigation of chemical aging in composite propellants through laser-induced breakdown spectroscopy (LIBS). Journal of Thermal Analysis and Calorimetry, 2016, 124, 279-286.	2.0	32
130	Factors Impacting Quality of Life in Thalassemia Patients; Results from the Intercontinenthal Collaborative Study. Blood, 2016, 128, 3633-3633.	0.6	15
131	Correlation of Serum Ferritin Levels with Liver and Heart Mri T2 and Liver Iron Concentration in Beta Thalassemia Intermediate Patients: A Contemporary Issue. Blood, 2016, 128, 4829-4829.	0.6	1
132	Prevalence of Discrepancy Between the Results of One-Stage and Chromogenic Factor VIII:C Assays in Iranian Patients with Mild / Moderate Hemophilia A. Blood, 2016, 128, 4982-4982.	0.6	1
133	Delay in Diagnosis of Hemoglobulinopathies (Thalassemia, Sickle Cell Anemia): A Need for Management of Thalassemia Programs. Iranian Journal of Pediatrics, 2016, 27, .	0.1	3
134	Breastfeeding as a Protective Effect Against Childhood Leukemia and Lymphoma. Iranian Red Crescent Medical Journal, 2016, 18, e29771.	0.5	6
135	Efficacy of Human Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and to Prevent Bleeding during and after Surgery in Subjects with Congenital Fibrinogen Deficiency. Blood, 2016, 128, 1404-1404.	0.6	0
136	A Large-Scale Prospective Cohort Study on Factor XIII Deficiency in Southeast of Iran. Blood, 2016, 128, 209-209.	0.6	1
137	Are Bleeding Scores Predicting Severity and Outcome in Hemophilia and Rare Bleeding Disorders?. Blood, 2016, 128, 4801-4801.	0.6	1
138	The Effect of Educational-Spiritual Intervention on The Burnout of The Parents of School Age Children with Cancer: A Randomized Controlled Clinical Trial. International Journal of Community Based Nursing and Midwifery, 2016, 4, 90-7.	0.2	11
139	Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin PÂ®. Iranian Journal of Pharmaceutical Research, 2016, 15, 635-40.	0.3	1
140	Hemoaction Game: An educational Step to Improve Hemophilia Children and Nurses Self-Efficacy. Journal of Advances in Medical Education and Professionalism, 2016, 4, 206.	0.2	1
141	Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran. International Journal of Hematology-Oncology and Stem Cell Research, 2016, 10, 224-231.	0.3	12
142	Effectiveness of Î²â€thalassemia prenatal diagnosis in Southern Iran: a cohort study. Prenatal Diagnosis, 2015, 35, 1238-1242.	1.1	8
143	Replacement therapy in inherited factor VII deficiency: occurrence of adverse events and relation with surgery. Haemophilia, 2015, 21, e513-7.	1.0	16
144	THE ICET-A SURVEY ON CURRENT CRITERIA USED BY CLINICIANS FOR THE ASSESSMENT OF CENTRAL ADRENAL INSUFFICIENCY IN THALASSEMIA: ANALYSIS OF RESULTS AND RECOMMENDATIONS. Mediterranean Journal of Hematology and Infectious Diseases, 2015, 8, e2016034.	0.5	12

#	Article	IF	Citations
145	Relationship Between Serum Hepcidin and Ferritin Levels in Patients With Thalassemia Major and Intermedia in Southern Iran. Iranian Red Crescent Medical Journal, 2015, 17, e28343.	0.5	16
146	Incidence of testicular microlithiasis in patients with Î²-thalassemia major. Annals of Hematology, 2015, 94, 1785-1789.	0.8	3
147	Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports. Hematology, 2015, 20, 53-57.	0.7	22
148	The effects of economic sanctions on disease specific clinical outcomes of patients with thalassemia and hemophilia in Iran. Health Policy, 2015, 119, 239-243.	1.4	29
149	Distribution of alpha-thalassemia mutations in Iranian population. Hematology, 2015, 20, 359-362.	0.7	23
150	Efficacy of Deferasirox (ExjadeÂ®) in Modulation of Iron Overload in Patients withÎ²-Thalassemia Intermedia. Hemoglobin, 2015, 39, 327-329.	0.4	9
151	The incidence of factor <scp>VIII</scp> inhibitors in severe haemophilia A following a major switch from fullâ€length to Bâ€domainâ€deleted factor <scp>VIII</scp>: a prospective cohort comparison. Haemophilia, 2015, 21, 219-226.	1.0	41
152	Combination therapyÂâ€“Âdeferasirox and deferoxamineÂâ€“Âin thalassemia major patients in emerging countries with limited resources. Transfusion Medicine, 2015, 25, 8-12.	0.5	17
153	A Comparison Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Congenital Factor VII Deficiency. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 724-728.	0.7	13
154	Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates in Patients with Congenital Fibrinogen Deficiency: Final Analysis. Blood, 2015, 126, 4680-4680.	0.6	3
155	Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study. Blood, 2015, 126, 5-5.	0.6	16
156	Infantile fibrosarcoma of ethmoid sinus, misdiagnosed as an adenoid in a 5-year-old child. Journal of Oral and Maxillofacial Pathology, 2015, 19, 271.	0.3	7
157	Serum Ferritin Levels Correlation With Heart and Liver MRI and LIC in Patients With Transfusion-Dependent Thalassemia. Iranian Red Crescent Medical Journal, 2015, 17, e24959.	0.5	37
158	Comparative Study of Radiographic and Laboratory Findings Between Beta Thalassemia Major and Beta Thalassemia Intermedia Patients With and Without Treatment by Hydroxyurea. Iranian Red Crescent Medical Journal, 2015, 17, e23607.	0.5	4
159	Quality of Life in Children with Rare Bleeding Disorders. Blood, 2015, 126, 4698-4698.	0.6	0
160	Effect of coping strategies training on its use by thalassemia major adolescents: a randomized controlled clinical trial. International Journal of Community Based Nursing and Midwifery, 2015, 3, 67-74.	0.2	4
161	The effect of yoga on the quality of life in the children and adolescents with haemophilia. International Journal of Community Based Nursing and Midwifery, 2015, 3, 150-5.	0.2	4
162	THE FREQUENCY OF ADRENAL INSUFFICIENCY IN ADOLESCENTS AND YOUNG ADULTS WITH THALASSEMIA MAJOR VERSUS THALASSEMIA INTERMEDIA IN IRAN. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 7, e2015005.	0.5	10

#	Article	IF	Citations
163	INSULIN-LIKE GROWTH FACTOR-1 (IGF-1): DEMOGRAPHIC, CLINICAL AND LABORATORY DATA IN 120 CONSECUTIVE ADULT PATIENTS WITH THALASSAEMIA MAJOR. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014074.	0.5	28
164	The effect of metoprolol succinate on the cardiac function of patients with thalassaemia cardiomyopathy: a double-blind randomised study. Heart Asia, 2014, 6, 54-58.	1.1	3
165	Evaluation of Red Cell Membrane Cytoskeletal Disorders Using a Flow Cytometric Method in South Iran. Turkish Journal of Haematology, 2014, 31, 25-31.	0.2	4
166	Compliance and satisfaction with deferasirox (Exjade^{Â®}) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia. Hematology, 2014, 19, 187-191.	0.7	24
167	Genotype and phenotype report on patients with combined deficiency of factor V and factor VIII in Iran. Blood Coagulation and Fibrinolysis, 2014, 25, 360-363.	0.5	14
168	Serum Level of Lactate Dehydrogenase is a Useful Clinical Marker to Monitor Progressive Multiple Myeloma Diseases: A Case Report. Turkish Journal of Haematology, 2014, 31, 84-87.	0.2	7
169	Intracranial hemorrhage pattern in the patients with factor XIII deficiency. Annals of Hematology, 2014, 93, 693-697.	0.8	21
170	Inhibitors to factor <scp>VII</scp> in congenital factor <scp>VII</scp> deficiency. Haemophilia, 2014, 20, e188-91.	1.0	27
171	An experience of using Traumastem P in control of spontaneous nose bleeding in patients with inherited bleeding disorders in southern <scp>I</scp>ran. Haemophilia, 2014, 20, e79-80.	1.0	3
172	Comparison of Thrombin Generation Assay With Conventional Coagulation Tests in Evaluation of Bleeding Risk in Patients With Rare Bleeding Disorders. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 637-644.	0.7	20
173	Spectrum of the Mutations in Bernard-Soulier Syndrome. Human Mutation, 2014, 35, 1033-1045.	1.1	124
174	Guidelines for Diagnosis and Management of Beta-Thalassemia Intermedia. Pediatric Hematology and Oncology, 2014, 31, 583-596.	0.3	61
175	Epidemiology of Hemoglobinopathies and Thalassemias in Individuals Referred to the Haematology Research Centre, Shiraz University of Medical Sciences, Shiraz, Iran From 2006 to 2011. Hemoglobin, 2014, 38, 287-288.	0.4	2
176	The burden and management of <scp>FXIII</scp> deficiency. Haemophilia, 2014, 20, 733-740.	1.0	15
177	Frequency of Cholelithiasis in Patients With Beta-Thalassemia Intermedia With and Without Hydroxyurea. Iranian Red Crescent Medical Journal, 2014, 16, e18712.	0.5	6
178	Pulmonary tuberculosis in migratory nomadic populations: the missing link in Iran's National Tuberculosis Programme. International Journal of Tuberculosis and Lung Disease, 2014, 18, 272-276.	0.6	12
179	Serum ferritin level and morbidity risk in transfusion-independent patients with Â-thalassemia intermedia: the ORIENT study. Haematologica, 2014, 99, e218-e221.	1.7	56
180	Clinical Manifestations and Bleeding Episodes Among Heterozygote Individuals of Factor XIII Deficiency, a Short Term Prospective Study. Blood, 2014, 124, 2852-2852.	0.6	3

#	Article	IF	Citations
181	Hydroxyurea Treatment in Transfusion-Dependent Î²-Thalassemia Patients. Iranian Red Crescent Medical Journal, 2014, 16, e18028.	0.5	24
182	Prevalence of thalassaemia, iron-deficiency anaemia and glucose-6-phosphate dehydrogenase deficiency among Arab migrating nomad children, southern Islamic Republic of Iran. Eastern Mediterranean Health Journal, 2014, 20, 726-731.	0.3	1
183	This Is a Title : Long Term succsesfull Prophylaxis in 190 Patients with Severe Congenital Factor XIII Deficiency, a Four Years Experience. Here Is the Sub-Title: Succsefull Prophylaxis in Factor XIII Deficiency. Blood, 2014, 124, 2851-2851.	0.6	0
184	A Comparison Between MRI, Sonography and FISH Methods in Diagnosis, Evaluation and Classification of Arthropathy in Severe Haemophilia a and B. Blood, 2014, 124, 5035-5035.	0.6	0
185	Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates for the Treatment of Congenital Fibrinogen Deficiency. Blood, 2014, 124, 2817-2817.	0.6	1
186	Evaluation of Thrombin Generation Assay in Patients with Hemophilia. Blood, 2014, 124, 5061-5061.	0.6	0
187	Hypothyroidism in Î²-Thalassemia Intermedia Patients with and without Hydroxyurea. Iranian Journal of Medical Sciences, 2014, 39, 60-3.	0.3	5
188	Frequency of Celiac Disease in Children with Beta Thalassemia major. Iranian Journal of Pediatric Hematology and Oncology, 2014, 4, 48-52.	0.4	2
189	Serum cancer antigen 15.3 concentrations in patients with betathalassemia minor compared to those with cancer and healthy individuals. Medical Journal of the Islamic Republic of Iran, 2014, 28, 91.	0.9	1
190	Prevalence of thalassaemia, iron-deficiency anaemia and glucose-6-phosphate dehydrogenase deficiency among Arab migrating nomad children, southern Islamic Republic of Iran. Eastern Mediterranean Health Journal, 2014, 20, 726-31.	0.3	1
191	Immunomodulatory effects of silymarin in patients with Î²-thalassemia major. International Immunopharmacology, 2013, 16, 243-247.	1.7	33
192	Costâ€“utility analysis of oral deferasirox versus infusional deferoxamine in transfusionâ€dependent Î²â€thalassemia patients. Transfusion, 2013, 53, 1722-1729.	0.8	16
193	Consensus recommendations for the use of FEIBA^{Â®} in haemophilia A patients with inhibitors undergoing elective orthopaedic and nonâ€orthopaedic surgery. Haemophilia, 2013, 19, 294-303.	1.0	39
194	Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. Indian Journal of Endocrinology and Metabolism, 2013, 17, 8.	0.2	105
195	Cerebral Artery Velocity Determined by Transcranial Doppler Ultrasonography in Patients With Î²-Thalassemia Intermedia Compared to Î²-Thalassemia Major. Clinical and Applied Thrombosis/Hemostasis, 2013, 19, 367-373.	0.7	1
196	Experience on Using Prothrombin Complex Concentrate in Urgent Warfarin Reversal. Clinical and Applied Thrombosis/Hemostasis, 2013, 19, 277-281.	0.7	4
197	Induction of HBF. Thalassemia Reports, 2013, 3, e39.	0.1	1
198	Determining and Surveying the Role of Carnitine and Folic Acid to Decrease Fatigue in Î²-Thalassemia Minor Subjects. Pediatric Hematology and Oncology, 2013, 30, 742-747.	0.3	8

#	Article	IF	Citations
199	Family Planning Practices in Families with Children Affected by Î²-Thalassemia Major in Southern Iran. Hemoglobin, 2013, 37, 74-79.	0.4	3
200	Attitudes and practices with regard to circumcision in haemophilia patients in Southern Iran. Haemophilia, 2013, 19, e177-8.	1.0	2
201	Evaluation of the FXIII deficiency prophylaxis intervals in large number of FXIII deficiency patients from Iran. Haemophilia, 2013, 19, e175-6.	1.0	5
202	Replacement therapy for bleeding episodes in factor VII deficiency. Thrombosis and Haemostasis, 2013, 109, 238-247.	1.8	48
203	Frequency of combined factor V and factor VIII deficiency in southern Iran. Blood Coagulation and Fibrinolysis, 2013, 24, 458-459.	0.5	1
204	Quality of life among Iranian patients with beta-thalassemia major using the SF-36 questionnaire. Sao Paulo Medical Journal, 2013, 131, 166-172.	0.4	33
205	Molecular Analysis Of The Largest Group Of Patients With Factor XIII Deficiency In Southeast Of Iran. Blood, 2013, 122, 4780-4780.	0.6	4
206	The PAI-I Gene 4G/5G Polymorphism and Central Nervous System Bleeding In Factor XIII Deficiency. Blood, 2013, 122, 4782-4782.	0.6	2
207	An MTHFR Variant, Plasma Homocysteine Levels and Late-Onset Coronary Artery Disease in Subjects from Southern Iran. Pakistan Journal of Biological Sciences, 2013, 16, 788-795.	0.2	4
208	Inherited Thrombophilia and Recurrent Pregnancy Loss. Iranian Red Crescent Medical Journal, 2013, 15, e13708.	0.5	20
209	Transcranial Doppler Ultrasonography in Beta-thalassemia Major Patients Without and With Thrombocytosis. Iranian Red Crescent Medical Journal, 2013, 15, 229-33.	0.5	1
210	Management of Bleeding in Post-liver Disease, Surgery and Biopsy in Patients With High Uncorrected International Normalized Ratio With Prothrombin Complex Concentrate: An Iranian Experience. Iranian Red Crescent Medical Journal, 2013, 15, e12260.	0.5	2
211	Diffuse hepatic calcifications in a transfusion-dependent patient with Beta-thalassemia: a case report. Iranian Journal of Medical Sciences, 2013, 38, 271-4.	0.3	0
212	Growth hormone deficiency in adults with thalassemia: an overview and the I-CET recommendations. Georgian Medical News, 2013, , 79-88.	0.0	11
213	Osteoporosis in thalassemia major: an update and the I-CET 2013 recommendations for surveillance and treatment. Pediatric Endocrinology Reviews, 2013, 11, 167-80.	1.2	30
214	Is zinc an essential factor in maternal health status and fetal and neonatal growth?. Trace Elements and Electrolytes, 2012, 29, 239-245.	0.1	1
215	Arg77His and Trp187Arg are the Most Common Mutations Causing FXIII Deficiency in Iran. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 100-103.	0.7	12
216	Sociocultural challenges of beta-thalassaemia major birth in carriers of beta-thalassaemia in Iran. Journal of Medical Screening, 2012, 19, 109-111.	1.1	10

#	Article	IF	Citations
217	Intracranial Blood Flow Velocity in Patients withÎ²-Thalassemia Intermedia Using Transcranial Doppler Sonography: A Case-Control Study. Anemia, 2012, 2012, 1-4.	0.5	9
218	Î²-Thalassemia: New Therapeutic Modalities, Genetics, Complications, and Quality of Life. Anemia, 2012, 2012, 1-1.	0.5	38
219	Comparative study of hypogonadism in beta-thalassemia intermedia patients with and without hydroxyurea. Hematology, 2012, 17, 122-124.	0.7	6
220	Iranian experience of deferasirox (Exjade^{Â®}) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels?. Hematology, 2012, 17, 367-371.	0.7	5
221	Cerebral thrombosis in patients with Î²-thalassemia. Blood Coagulation and Fibrinolysis, 2012, 23, 212-217.	0.5	31
222	Contemporary approaches to treatment of beta-thalassemia intermedia. Blood Reviews, 2012, 26, S24-S27.	2.8	40
223	Genotypeâ€“phenotype correlation related to lipid profile in beta-thalassemia major and intermedia in southern Iran. Journal of Clinical Lipidology, 2012, 6, 108-113.	0.6	7
224	Is the Apolipoprotein E4 Allele Always Hazardous? Serum Uric Acid Level as a Conflict. Genetic Testing and Molecular Biomarkers, 2012, 16, 920-923.	0.3	3
225	Successful delivery in patients with FXIII deficiency receiving prophylaxis: report of 17 cases in Iran. Haemophilia, 2012, 18, 773-776.	1.0	17
226	Cerebral infarction in Î²-thalassemia intermedia: Breaking the silence. Thrombosis Research, 2012, 130, 695-702.	0.8	81
227	Thyroid function and stress hormones in children with stress hyperglycemia. Endocrine, 2012, 42, 653-657.	1.1	4
228	Frequency and distribution of asymptomatic brain lesions in patients with Î²-thalassemia intermedia. Annals of Hematology, 2012, 91, 1833-1838.	0.8	18
229	Attitudes of haemophilic patients towards their health and socioâ€economic problems in Iran. Haemophilia, 2012, 18, 122-128.	1.0	9
230	Efficacy of prophylaxis and genotypeâ€phenotype correlation in patients with severe Factor X deficiency in Iran. Haemophilia, 2012, 18, 211-215.	1.0	34
231	Retrospective evaluation of bleeding tendency and simultaneous thrombin and plasmin generation in patients with rare bleeding disorders. Haemophilia, 2012, 18, 630-638.	1.0	26
232	Compliance of deferoxamine injection in betaâ€thalassaemia major patients in Iran. Transfusion Medicine, 2012, 22, 104-107.	0.5	9
233	Polymorphisms associated with sickle cell disease in Southern Iran. Russian Journal of Genetics, 2012, 48, 755-757.	0.2	0
234	Genotypeâ€“phenotype relationship of patients with Î²-thalassemia taking hydroxyurea: a 13-year experience in Iran. International Journal of Hematology, 2012, 95, 51-56.	0.7	50

#	Article	IF	Citations
235	Serum Ferritin Levels and Morbidity in Î²-Thalassemia Intermedia: A 10-Year Cohort Study. Blood, 2012, 120, 1021-1021.	0.6	11
236	Frequency and Distribution of Asymptomatic Brain Lesions in Patients with Î²-Thalassemia Intermedia. Blood, 2012, 120, 5141-5141.	0.6	0
237	Prophylactic Program in fxiii Deficient Patients From Iran. Blood, 2012, 120, 3376-3376.	0.6	0
238	Pulmonary Function Test in Transfusion-Dependent Î²-Thalassemia Major Patients: A Pilot Study. Pediatric Hematology and Oncology, 2011, 28, 329-333.	0.3	11
239	Risk factors for pulmonary hypertension in patients with Î² thalassemia intermedia. European Journal of Internal Medicine, 2011, 22, 607-610.	1.0	56
240	Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran. ClinicoEconomics and Outcomes Research, 2011, 3, 207.	0.7	24
241	Bleeding symptoms in heterozygous carriers of inherited coagulation disorders in southern Iran. Blood Coagulation and Fibrinolysis, 2011, 22, 396-401.	0.5	16
242	Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease in southern Iran. Blood Coagulation and Fibrinolysis, 2011, 22, 325-330.	0.5	1
243	Inhibitors of coagulation. Haemophilia, 2011, 17, 90-94.	1.0	6
244	Experience of four UK comprehensive care centres using FEIBA^{Â®} for surgeries in patients with inhibitors. Haemophilia, 2011, 17, 28-34.	1.0	38
245	Bone mineral density in Iranian patients with haemophilia: the first experience in southern Iran. Haemophilia, 2011, 17, 552-553.	1.0	12
246	Long-term follow-up of prophylaxis with recombinant activated factor VII in patients with congenital factor VII deficiency. Haemophilia, 2011, 17, 713-715.	1.0	7
247	The correlation between gene mutations and inhibitor development in patients with haemophilia A in southern Iran. Haemophilia, 2011, 17, 820-821.	1.0	2
248	D-dimer level in pediatric patients with solid and hematologic malignancies, Shiraz, Southern Iran. International Journal of Laboratory Hematology, 2011, 33, e22-e24.	0.7	1
249	Comparative study of pulmonary circulation and myocardial function in patients with Î²-thalassemia intermedia with and without hydroxyurea, a case-control study. European Journal of Haematology, 2011, 87, 61-67.	1.1	14
250	How to deal with medical and social aspects of bleeding disorders â€“ preparing women and the family in developing countries. Haemophilia, 2011, 17, 42-44.	1.0	5
251	Use of Glubran 2 and Glubran tissue skin adhesive in patients with hereditary bleeding disorders undergoing circumcision and dental extraction. Annals of Hematology, 2011, 90, 463-468.	0.8	12
252	Synoviorthesis induced by rifampicin in hemophilic arthropathy: a report of 24 treated joints. Annals of Hematology, 2011, 90, 963-969.	0.8	12

#	Article	IF	Citations
253	Early Echocardiographic Findings in Î²-Thalassemia Intermedia Patients Using Standard and Tissue Doppler Methods. Pediatric Cardiology, 2011, 32, 154-159.	0.6	16
254	Diagnosis and Management ofvon Willebrand Disease in Iran. Seminars in Thrombosis and Hemostasis, 2011, 37, 602-606.	1.5	8
255	Causes for Hospitalization and Death in Iranian Patients with Î²-Thalassemia Major. Pediatric Hematology and Oncology, 2011, 28, 134-139.	0.3	19
256	Protein C concentration in newborn infants with sepsis-like illness. Journal of Neonatal-Perinatal Medicine, 2011, 4, 55-58.	0.4	0
257	Detection of Hb Setif in North Iran and the Question of Its Origin: Iranian or Multiethnic?. Hemoglobin, 2011, 35, 152-156.	0.4	5
258	Management of the Sponataneous Bleeding Episodes in Factor VII Deficiency. A Prospective Evaluation of the STER,. Blood, 2011, 118, 3368-3368.	0.6	0
259	International Consortium for the Study of Clinical and Molecular Aspects of Bernard-Soulier Syndrome. Blood, 2011, 118, 707-707.	0.6	0
260	Cerebral Artery Velocity in Patients with Î²-Thalassemia Intermedia Compared to Î²-Thalassemia Major Using Transcranial Doppler Ultrasonography,. Blood, 2011, 118, 3335-3335.	0.6	0
261	Successful Delivery of Patients with FXIII Deficiency on Prophylaxis in Iran. Blood, 2011, 118, 4363-4363.	0.6	2
262	Maternal and prenatal risk factors for childhood leukemia in southern of iran. Iranian Red Crescent Medical Journal, 2011, 13, 398-403.	0.5	8
263	Initial presentation of acute lymphoblastic leukemia with osteoporosis and multiple spontaneous bone fractures. Iranian Red Crescent Medical Journal, 2011, 13, 52-4.	0.5	4
264	Major causes of hospital admission in Beta thalassemia major patients in southern iran. Iranian Journal of Pediatrics, 2011, 21, 509-13.	0.1	9
265	The pregnancy outcome in patients with minor Î²-thalassemia. Iranian Journal of Reproductive Medicine, 2011, 9, 9-14.	0.8	11
266	Seroprevalence of Human Herpes Simplex, Hepatitis B and Epstein-Barr Viruses in Children with Acute Lymphoblastic Leukemia in Southern Iran. Pathology and Oncology Research, 2010, 16, 579-582.	0.9	13
267	Effect of combination therapy of hydroxyurea with <scp>l</scp>â€carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with Î²â€thalassemia intermedia. European Journal of Haematology, 2010, 84, 52-58.	1.1	22
268	Risk factors for pulmonary hypertension in patients with thalassemia intermedia. European Journal of Haematology, 2010, 85, 549-551.	1.1	15
269	Splenectomy and thrombosis: the case of thalassemia intermedia. Journal of Thrombosis and Haemostasis, 2010, 8, 2152-2158.	1.9	120
270	Longâ€term prophylaxis in patients with factor XIII deficiency complicated by intracranial haemorrhage in Iran. Haemophilia, 2010, 16, 383-385.	1.0	12

#	Article	IF	Citations
271	Ageâ€related complications in treatmentâ€naÃ¯ve patients with thalassaemia intermedia. British Journal of Haematology, 2010, 150, 486-489.	1.2	100
272	Haemophilia in the developing countries: the Iranian experience. Archives of Medical Science, 2010, 1, 83-89.	0.4	16
273	The Efficacy of a Neonatal Screening Programme in Decreasing the Hospitalization Rate of Patients with G6pd Deficiency in Southern Iran. Journal of Medical Screening, 2010, 17, 66-67.	1.1	14
274	Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood, 2010, 115, 1886-1892.	0.6	315
275	Magnetic resonance imaging to determine the incidence of brain ischaemia in patients with Î²-thalassaemia intermedia. Thrombosis and Haemostasis, 2010, 103, 989-993.	1.8	42
276	Attitude Toward Prenatal Diagnosis for Î²-Thalassemia Major and Medical Abortion in Southern Iran. Hemoglobin, 2010, 34, 49-54.	0.4	13
277	ADVERSE EFFECTS OF HYDROXYUREA IN Î²-THALASSEMIA INTERMEDIA PATIENTS: 10 Yearsâ€™ Experience. Pediatric Hematology and Oncology, 2010, 27, 205-211.	0.3	33
278	Frequency of Afterload Homocysteinemia in Normal Population of Southern Iran: A Pilot Study. Pakistan Journal of Biological Sciences, 2010, 13, 352-354.	0.2	2
279	Cancer-Associated Thrombosis~!2009-11-10~!2009-12-11~!2010-02-22~!. Open Cardiovascular Medicine Journal, 2010, 4, 78-82.	0.6	28
280	Serum lipid profiles in patients with beta-thalassemia major and intermedia in southern Iran. Journal of Research in Medical Sciences, 2010, 15, 150-4.	0.4	17
281	Efficacy of Carvedilol in Patients with Dilated Cardiomyopathy due to Beta-thalassemia major; a Double-blind Randomized Controlled Trial. Iranian Journal of Pediatrics, 2010, 20, 277-83.	0.1	5
282	Frequency of sensory neural hearing loss in major Beta-thalassemias in southern iran. Iranian Journal of Pediatrics, 2010, 20, 308-12.	0.1	4
283	The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura. Haematologica, 2009, 94, 289-293.	1.7	22
284	Does Helicobacter Pylori Play A Role in the Pathogenesis of Childhood Chronic Idiopathic Thrombocytopenic Purpura?. Mental Illness, 2009, 1, e2.	0.8	10
285	Factor XIII Deficiency. Seminars in Thrombosis and Hemostasis, 2009, 35, 426-438.	1.5	197
286	Radiofrequency Ablation of the Spleen in Patients with Thalassemia Intermedia: A Pilot Study. American Journal of Roentgenology, 2009, 192, 1425-1429.	1.0	10
287	Echocardiographic finding in betaâ€thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in betaâ€thalassemia intermedia. European Journal of Haematology, 2009, 82, 213-218.	1.1	37
288	Is red cell from an otherwise healthy G6PD-deficient donor efficient for transfusion to fauvism patients?. Indian Journal of Hematology and Blood Transfusion, 2009, 25, 23-26.	0.3	1

#	Article	IF	Citations
289	Double-faced cell-mediated immunity in Î²-thalassemia major: stimulated phenotype versus suppressed activity. Annals of Hematology, 2009, 88, 21-27.	0.8	45
290	Factor XI deficiency in Southern Iran: identification of a novel missense mutation. Annals of Hematology, 2009, 88, 359-363.	0.8	7
291	Malignancies in patients with Î²â€thalassemia major and Î²â€thalassemia intermedia: A multicenter study in Iran. Pediatric Blood and Cancer, 2009, 53, 1064-1067.	0.8	26
292	Home therapy and the effect of educational programmes in Iran; an alternative treatment option in developing countries. Haemophilia, 2009, 15, 966-967.	1.0	3
293	Combined therapy of silymarin and desferrioxamine in patients with Î²â€thalassemia major: a randomized doubleâ€blind clinical trial. Fundamental and Clinical Pharmacology, 2009, 23, 359-365.	1.0	46
294	Prevalence of hepatosplenomegaly in beta thalassemia minor subjects in Iran. European Journal of Radiology, 2009, 69, 120-122.	1.2	19
295	Hypoparathyroidism and intracerebral calcification in patients with beta-thalassemia major. European Journal of Radiology, 2009, 70, 481-484.	1.2	22
296	Malignant epithelioid hemangioendothelioma of the bladder: the first case report in a child. Journal of Pediatric Surgery, 2009, 44, 1443-1445.	0.8	10
297	Hydroxyurea in the Management of Thalassemia Intermedia. Hemoglobin, 2009, 33, S177-S182.	0.4	18
298	Multi Centric Origin of Hb D-Punjab [Î²121(GH4)Gluâ†'Gln,GAA>CAA]. Hemoglobin, 2009, 33, 399-405.	0.4	21
299	Spectrum of inherited bleeding disorders in southern Iran, before and after the establishment of comprehensive coagulation laboratory. Blood Coagulation and Fibrinolysis, 2009, 20, 642-645.	0.5	17
300	Initial presentation of childhood leukaemia with facial palsy: three case reports. BMJ Case Reports, 2009, 2009, bcr1020081046-bcr1020081046.	0.2	9
301	Apolipoprotein E polymorphism in Southern Iran: E4 allele in the lowest reported amounts. Molecular Biology Reports, 2008, 35, 495-499.	1.0	33
302	Termination of pregnancy due to Thalassemia major, Hemophilia, and Down's Syndrome: the views of Iranian physicians. BMC Medical Ethics, 2008, 9, 19.	1.0	10
303	Cerebrovascular accident in Î²-thalassemia major (Î²-TM) and Î²-thalassemia intermedia (Î²-TI). American Journal of Hematology, 2008, 83, 77-79.	2.0	47
304	Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). Journal of Thrombosis and Haemostasis, 2008, 6, 1534-1541.	1.9	57
305	Health status in Iranian haemophilic patients. Haemophilia, 2008, 14, 615-617.	1.0	5
306	Prophylactic effect of recombinant factor VIIa with congenital factor VII deficiency. Haemophilia, 2008, 14, 851-852.	1.0	9

#	Article	IF	Citations
307	Prevalence of Î²-Thalassemia Trait and Glucose-6-Phosphate Dehydrogenase Deficiency in Iranian Jews. Archives of Medical Research, 2008, 39, 212-214.	1.5	21
308	The prevalence of signs and symptoms of childhood leukemia and lymphoma in Fars Province, Southern Iran. Cancer Detection and Prevention, 2008, 32, 178-183.	2.1	29
309	Is Î²-Thalassemia Trait a Protective Factor Against Ischemic Cerebrovascular Accidents?. Journal of Stroke and Cerebrovascular Diseases, 2008, 17, 79-81.	0.7	12
310	Prevalence of pyruvate kinase deficiency among the south Iranian population: Quantitative assay and molecular analysis. Blood Cells, Molecules, and Diseases, 2008, 40, 308-311.	0.6	10
311	Successful Control of Central Nervous System Bleeding in Two Newborns With Severe Factor VII Deficiency Using rFVIIa Administered via Port-a-Cath. Seminars in Hematology, 2008, 45, S74.	1.8	7
312	A lump on the head. Lancet, The, 2008, 372, 1436.	6.3	4
313	Evaluation of prevalence of drug dependence in betaâ€thalassemic patients and its risk factors. Journal of Substance Use, 2008, 13, 293-298.	0.3	0
314	Phenotype and genotype report on homozygous and heterozygous patients with congenital factor X deficiency. Haematologica, 2008, 93, 934-938.	1.7	47
315	ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica, 2008, 93, 232-239.	1.7	250
316	Sociocultural Challenges of Thalassemia Birth in Islamic and Developing Countries. Journal of Pediatric Hematology/Oncology, 2008, 30, 335.	0.3	4
317	Quality of life in thalassemia major. Journal of Postgraduate Medicine, 2008, 54, 273-275.	0.2	40
318	Pregnancy outcomes in asthmatic women. Iranian Journal of Allergy, Asthma and Immunology, 2008, 7, 105-6.	0.3	6
319	Genetic characterization of patients with Bernard-Soulier syndrome and their relatives from Southern Iran. Platelets, 2007, 18, 409-413.	1.1	13
320	Premarital screening for Î²-thalassaemia in Southern Iran: options for improving the programme. Journal of Medical Screening, 2007, 14, 62-66.	1.1	66
321	Magnetic Resonance Imaging (MRI) Findings of Joints in Young Î²-Thalassemia Major Patients: Fluid Surrounding the Scaphoid Bone. Journal of Pediatric Hematology/Oncology, 2007, 29, 393-398.	0.3	3
322	The Protective Effects of Ginkgo Biloba Extract in Decreasing Hemolysis of RBC in Glucose-6-phosphate Dehydrogenase-deficient Patients. Journal of Pediatric Hematology/Oncology, 2007, 29, 511-512.	0.3	4
323	Substance dependency in Iranian patients with hemophilia. Addictive Behaviors, 2007, 32, 365-369.	1.7	9
324	Apolipoprotein E gene polymorphism and left ventricular function in Iranian patients with thalassemia major. Haematologica, 2007, 92, 256-257.	1.7	10

#	Article	IF	Citations
325	Mutational screening of six afibrinogenemic patients: Identification and characterization of four novel molecular defects. Thrombosis and Haemostasis, 2007, 97, 546-551.	1.8	21
326	Antiphospholipid antibodies and hepatitis C virus infection in Iranian thalassemia major patients. International Journal of Laboratory Hematology, 2007, 30, 070405061157003-???.	0.2	11
327	RBC alloimmunization in blood transfusion-dependent ?-thalassemia patients in southern Iran. International Journal of Laboratory Hematology, 2007, 29, 321-326.	0.7	63
328	Bone mineral density in beta-thalassemia major and intermedia. Indian Pediatrics, 2007, 44, 29-32.	0.2	41
329	HODGKIN LYMPHOMA DEVELOPING IN A 4.5-YEAR-OLD GIRL WITH HYPER-IgE SYNDROME. Pediatric Hematology and Oncology, 2006, 23, 59-63.	0.3	20
330	Changing epidemiology of the hemolytic uremic syndrome and thrombotic thrombocytopenic purpura in southern Iran. Journal of Thrombosis and Haemostasis, 2006, 4, 701-702.	1.9	4
331	Is Î²-thalassemia trait a protective factor against hypertension in young adults?. Annals of Hematology, 2006, 85, 29-31.	0.8	17
332	Is Î²-thalassemia trait a risk factor for developing depression in young adults?. Annals of Hematology, 2006, 85, 873-874.	0.8	12
333	Clinical and laboratory patterns of the haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura in southern Iran. Internal and Emergency Medicine, 2006, 1, 35-39.	1.0	7
334	Unusual lymphoblastic leukemia/lymphoma in Eastern Iran. Indian Journal of Pediatrics, 2006, 73, 619-622.	0.3	3
335	Clinical response of patients with sickle cell anemia to cromolyn sodium nasal spray. American Journal of Hematology, 2006, 81, 809-816.	2.0	13
336	Multitypic Hepatitis C Virus Infection Identified by Real-Time Nucleotide Sequencing of Minority Genotypes. Journal of Clinical Microbiology, 2006, 44, 2779-2784.	1.8	19
337	Analysis of intelligence quotient in patients with homozygous beta-thalassemia. Journal of King Abdulaziz University, Islamic Economics, 2006, 27, 982-5.	0.5	10
338	Hematologic and Clinical Responses of Thalassemia Intermedia Patients to Hydroxyurea During 6 Years of Therapy in Iran. Journal of Pediatric Hematology/Oncology, 2005, 27, 380-385.	0.3	79
339	Investigation of Helicobacter pylori infection in ??-thalassaemia major patients with recurrent abdominal pain. European Journal of Gastroenterology and Hepatology, 2005, 17, 1363-1367.	0.8	9
340	Glanzmann thrombasthenia and Bernard-Soulier syndrome in south Iran. International Journal of Laboratory Hematology, 2005, 27, 324-327.	0.2	17
341	Molecular Basis of Hb H Disease in Southwest Iran. Hemoglobin, 2005, 29, 43-50.	0.4	2
342	Molecular Basis of Hb H Disease in Southwest Iran. Hemoglobin, 2005, 29, 43-50.	0.4	17

#	Article	IF	Citations
343	Spectrum and haplotypes of the HFE hemochromatosis gene in Iran: H63D in Î²-thalassemia major and the first E277K homozygous. The Hematology Journal, 2004, 5, 524-527.	2.0	22
344	Comparison of attitudes towards prenatal diagnosis and termination of pregnancy for haemophilia in Iran and Italy. Haemophilia, 2004, 10, 367-369.	1.0	25
345	Mutation Analysis in F9 Gene of 17 Families with Haemophilia B from Iran. Haemophilia, 2004, 10, 751-755.	1.0	10
346	Successful treatment of cyclophosphamide induced intractable hemorrhagic cystitis with recombinant FVIIa (NovoSevenR) after allogenic bone marrow transplantation. Journal of Thrombosis and Haemostasis, 2004, 2, 1853-1855.	1.9	26
347	A rare inherited coagulation disorder: Combined homozygous factor VII and factor X deficiency. American Journal of Hematology, 2004, 77, 90-91.	2.0	26
348	Phenotype-genotype characterization of 10 families with severe a subunit factor XIII deficiency. Human Mutation, 2004, 23, 98-98.	1.1	45
349	Intrathoracic Masses Due to Extramedullary Hematopoiesis. American Journal of the Medical Sciences, 2004, 328, 299-303.	0.4	26
350	Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. Haematologica, 2004, 89, 1172-8.	1.7	89
351	Short stature in beta-thalassemia minor subjects. Medical Science Monitor, 2004, 10, CR603-5.	0.5	4
352	Seasonal variations in the onset of childhood leukemia/lymphoma: April 1996 to March 2000, Shiraz, Iran. Hematological Oncology, 2003, 21, 51-55.	0.8	27
353	?-Globin gene cluster haplotypes in sickle cell patients from southwest Iran. American Journal of Hematology, 2003, 74, 156-160.	2.0	34
354	Hypoparathyroidism with Extensive Intracerebral Calcification in Patients with ÃŸ-Thalassemia Major. Journal of Pediatric Endocrinology and Metabolism, 2003, 16, 883-6.	0.4	14
355	Prevalence of iron deficiency anemia in 6 months to 5 years old children in Fars, Southern Iran. Medical Science Monitor, 2003, 9, CR100-4.	0.5	20
356	Molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Fars province of Iran. Haematologica, 2003, 88, 346-7.	1.7	17
357	Î²-THALASSEMIA INTERMEDIA FROM SOUTHERN IRAN: IVS-II-1 (Gâ†'A) IS THE PREVALENT THALASSEMIA INTERMEDIA ALLELE. Hemoglobin, 2002, 26, 147-154.	0.4	44
358	Evaluation of the Incidence of Sensorineural Hearing Loss in Beta-Thalassemia major Patients under Regular Chelation Therapy with Desferrioxamine. Acta Haematologica, 2002, 108, 79-83.	0.7	31
359	Efficiency of premarital screening of beta-thalassemia trait using MCH rather than MCV in the population of Fars Province, Iran. Haematologia, 2002, 32, 129-133.	0.2	20
360	Fine Needle Aspiration of Langerhans Cell Histiocytosis of the Lymph Nodes. Acta Cytologica, 2002, 46, 753-756.	0.7	20

#	Article	IF	Citations
361	Allele Frequency of CYP2C9 Gene Polymorphisms in Iran. Thrombosis and Haemostasis, 2002, 88, 874-875.	1.8	16
362	Cytology of Leukemic Lymphadenopathy. Acta Cytologica, 2002, 46, 801-807.	0.7	8
363	Inherited coagulation disorders in southern Iran. Haemophilia, 2002, 8, 740-744.	1.0	42
364	Assessment of the prevalence of iron deficiency anemia, by serum ferritin, in pregnant women of Southern Iran. Medical Science Monitor, 2002, 8, CR488-92.	0.5	14
365	Epidemiological surveillance of pediatric Hodgkin's disease in southern Iran. Medical Science Monitor, 2002, 8, CR572-5.	0.5	6
366	An analysis of prognostic factors and the five-year survival rate in childhood acute lymphoblastic leukemia. Medical Science Monitor, 2002, 8, CR792-6.	0.5	11
367	Seroprevalence of hepatitis B, hepatitis C and human immunodeficiency virus antibodies among multitransfused thalassaemic children in Shiraz, Iran. Journal of Paediatrics and Child Health, 2001, 37, 564-566.	0.4	37
368	Seroprevalence of HBsAg, anti-HCV,and anti-HIV among haemophiliac patients in Shiraz, Iran. Haematologia, 2001, 31, 251-255.	0.2	16
369	Subclassification of Localized Leishmania Lymphadenitis in Fine Needle Aspiration Smears. Acta Cytologica, 2001, 45, 547-554.	0.7	13